Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, what percentage of patients will have actionable genomic alterations detected by NGS-based technologies? (French)

Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, what percentage of patients will have actionable genomic alterations detected by NGS-based technologies? (French)

Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, approximately what percentage of patients will have actionable genomic alterations—EGFR, ALK, HER-2, RAS, and others—that are detected by FoundationOne or other NGS-based technologies? (French)


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France